Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aliskiren | The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Saralasin. |
| Canagliflozin | The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Saralasin. |
| Drospirenone | The risk or severity of hyperkalemia can be increased when Saralasin is combined with Drospirenone. |
| Eplerenone | The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Saralasin. |
| Semuloparin | The risk or severity of hyperkalemia can be increased when Semuloparin is combined with Saralasin. |
| Methyclothiazide | Methyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Bendroflumethiazide | Bendroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Benzthiazide | Benzthiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Cyclothiazide | Cyclothiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Hydroflumethiazide | Hydroflumethiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Chlorothiazide | Chlorothiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Hydrochlorothiazide | Hydrochlorothiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Trichlormethiazide | Trichlormethiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Polythiazide | Polythiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Mebutizide | Mebutizide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Cyclopenthiazide | Cyclopenthiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Buthiazide | Buthiazide may increase the hypotensive and Electrolyte Disturbance activities of Saralasin. |
| Lithium citrate | The serum concentration of Lithium citrate can be increased when it is combined with Saralasin. |
| Lithium carbonate | The serum concentration of Lithium carbonate can be increased when it is combined with Saralasin. |
| Lithium hydroxide | The serum concentration of Lithium hydroxide can be increased when it is combined with Saralasin. |
| Tolvaptan | The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Saralasin. |
| Trimethoprim | The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Saralasin. |
| Reserpine | Saralasin may decrease the antihypertensive activities of Reserpine. |
| Torasemide | Saralasin may decrease the antihypertensive activities of Torasemide. |
| Guanadrel | Saralasin may decrease the antihypertensive activities of Guanadrel. |
| Chlorthalidone | Saralasin may decrease the antihypertensive activities of Chlorthalidone. |
| Nitroprusside | Saralasin may decrease the antihypertensive activities of Nitroprusside. |
| Minoxidil | Saralasin may decrease the antihypertensive activities of Minoxidil. |
| Treprostinil | Saralasin may decrease the antihypertensive activities of Treprostinil. |
| Prazosin | Saralasin may decrease the antihypertensive activities of Prazosin. |
| Metolazone | Saralasin may decrease the antihypertensive activities of Metolazone. |
| Bosentan | Saralasin may decrease the antihypertensive activities of Bosentan. |
| Doxazosin | Saralasin may decrease the antihypertensive activities of Doxazosin. |
| Candoxatril | Saralasin may decrease the antihypertensive activities of Candoxatril. |
| Mecamylamine | Saralasin may decrease the antihypertensive activities of Mecamylamine. |
| Nitroglycerin | Saralasin may decrease the antihypertensive activities of Nitroglycerin. |
| Metyrosine | Saralasin may decrease the antihypertensive activities of Metyrosine. |
| Cryptenamine | Saralasin may decrease the antihypertensive activities of Cryptenamine. |
| Fenoldopam | Saralasin may decrease the antihypertensive activities of Fenoldopam. |
| Indapamide | Saralasin may decrease the antihypertensive activities of Indapamide. |
| Tadalafil | Saralasin may decrease the antihypertensive activities of Tadalafil. |
| Methyldopa | Saralasin may decrease the antihypertensive activities of Methyldopa. |
| Deserpidine | Saralasin may decrease the antihypertensive activities of Deserpidine. |
| Pentolinium | Saralasin may decrease the antihypertensive activities of Pentolinium. |
| Trimethaphan | Saralasin may decrease the antihypertensive activities of Trimethaphan. |
| Bretylium | Saralasin may decrease the antihypertensive activities of Bretylium. |
| Terazosin | Saralasin may decrease the antihypertensive activities of Terazosin. |
| Guanethidine | Saralasin may decrease the antihypertensive activities of Guanethidine. |
| Epoprostenol | Saralasin may decrease the antihypertensive activities of Epoprostenol. |
| Hydralazine | Saralasin may decrease the antihypertensive activities of Hydralazine. |
| Dexpropranolol | Saralasin may decrease the antihypertensive activities of Dexpropranolol. |
| Tienilic acid | Saralasin may decrease the antihypertensive activities of Tienilic acid. |
| Debrisoquine | Saralasin may decrease the antihypertensive activities of Debrisoquine. |
| Sitaxentan | Saralasin may decrease the antihypertensive activities of Sitaxentan. |
| Ambrisentan | Saralasin may decrease the antihypertensive activities of Ambrisentan. |
| Diethylnorspermine | Saralasin may decrease the antihypertensive activities of Diethylnorspermine. |
| Pinacidil | Saralasin may decrease the antihypertensive activities of Pinacidil. |
| Riociguat | Saralasin may decrease the antihypertensive activities of Riociguat. |
| Macitentan | Saralasin may decrease the antihypertensive activities of Macitentan. |
| Hexamethonium | Saralasin may decrease the antihypertensive activities of Hexamethonium. |
| Trimazosin | Saralasin may decrease the antihypertensive activities of Trimazosin. |
| Rauwolfia serpentina root | Saralasin may decrease the antihypertensive activities of Rauwolfia serpentina root. |
| Selexipag | Saralasin may decrease the antihypertensive activities of Selexipag. |
| Angiotensin 1-7 | Saralasin may decrease the antihypertensive activities of Angiotensin 1-7. |
| BQ-123 | Saralasin may decrease the antihypertensive activities of BQ-123. |
| Cicletanine | Saralasin may decrease the antihypertensive activities of Cicletanine. |
| Dihydralazine | Saralasin may decrease the antihypertensive activities of Dihydralazine. |
| Guanoxan | Saralasin may decrease the antihypertensive activities of Guanoxan. |
| Vincamine | Saralasin may decrease the antihypertensive activities of Vincamine. |
| Linsidomine | Saralasin may decrease the antihypertensive activities of Linsidomine. |
| Guanoxabenz | Saralasin may decrease the antihypertensive activities of Guanoxabenz. |
| Tolonidine | Saralasin may decrease the antihypertensive activities of Tolonidine. |
| Endralazine | Saralasin may decrease the antihypertensive activities of Endralazine. |
| Cadralazine | Saralasin may decrease the antihypertensive activities of Cadralazine. |
| Bietaserpine | Saralasin may decrease the antihypertensive activities of Bietaserpine. |
| Guanazodine | Saralasin may decrease the antihypertensive activities of Guanazodine. |
| Methoserpidine | Saralasin may decrease the antihypertensive activities of Methoserpidine. |
| Guanoclor | Saralasin may decrease the antihypertensive activities of Guanoclor. |
| Muzolimine | Saralasin may decrease the antihypertensive activities of Muzolimine. |
| Xipamide | Saralasin may decrease the antihypertensive activities of Xipamide. |
| Tocopherylquinone | Saralasin may decrease the antihypertensive activities of Tocopherylquinone. |
| Diazoxide | Saralasin may decrease the antihypertensive activities of Diazoxide. |
| Levamlodipine | Saralasin may decrease the antihypertensive activities of Levamlodipine. |
| Desmopressin | The risk or severity of hypertension can be increased when Desmopressin is combined with Saralasin. |
| Amphetamine | The risk or severity of hypertension can be increased when Amphetamine is combined with Saralasin. |
| Phentermine | The risk or severity of hypertension can be increased when Phentermine is combined with Saralasin. |
| Midodrine | The risk or severity of hypertension can be increased when Midodrine is combined with Saralasin. |
| Eletriptan | The risk or severity of hypertension can be increased when Eletriptan is combined with Saralasin. |
| Bethanidine | Saralasin may decrease the antihypertensive activities of Bethanidine. |
| Isoetharine | The risk or severity of hypertension can be increased when Isoetharine is combined with Saralasin. |
| Ziprasidone | The risk or severity of hypertension can be increased when Ziprasidone is combined with Saralasin. |
| Methysergide | The risk or severity of hypertension can be increased when Methysergide is combined with Saralasin. |
| Cabergoline | The risk or severity of hypertension can be increased when Cabergoline is combined with Saralasin. |
| Atomoxetine | The risk or severity of hypertension can be increased when Atomoxetine is combined with Saralasin. |
| Etomidate | The risk or severity of hypertension can be increased when Etomidate is combined with Saralasin. |
| Zolmitriptan | The risk or severity of hypertension can be increased when Zolmitriptan is combined with Saralasin. |
| Dihydroergotamine | The risk or severity of hypertension can be increased when Dihydroergotamine is combined with Saralasin. |
| Amitriptyline | The risk or severity of hypertension can be increased when Amitriptyline is combined with Saralasin. |
| Protriptyline | The risk or severity of hypertension can be increased when Protriptyline is combined with Saralasin. |
| Methylergometrine | The risk or severity of hypertension can be increased when Methylergometrine is combined with Saralasin. |